FINWIRES · TerminalLIVE
FINWIRES

Canada's Government Bond Auction Sizes May Remain High in Next Months, Says National Bank

作者

-- Canadian gross treasury bill issuance is rising to $30 billion this week, or $2 billion higher, said National Bank of Canada.

Of that, the Bank of Canada will buy $300 million, or 1% of the tender. Including cash management bills, $31 billion will mature Tuesday, leaving no net new supply for investors, noted the bank. By the end of week, the bill stock will stand at $285 billion.

The government's Spring Economic Update ushered in a downward revision to the bill stock target. By the end

of March 2027, outstanding bills are now expected to settle at $268 billion, stated National Bank. Indicatively, this could be accomplished with average auction sizes of $22 billion.

In reality, auction sizes will differ and they may remain high in the coming months (in part to fund bond maturities

in June, August and September) before easing in the fall, pointed out the bank.

BoC rate hike expectations rebounded since last auction as oil prices rose and markets interpreted the late April decision hawkishly. Indeed, investors keyed on Macklem's quote in the press conference where he threatened "consecutive" rate hikes if oil prices continue to increase, remain elevated and becomes ongoing generalized inflation.

To be sure, this is a risk, added the bank. However, it's clear that this is far from the BoC's base case. As part of the decision, they also provided updated economic and inflation projections. Notably, the central bank revised down its projection for core inflation in 2026.

So, while the BoC acknowledges that overall inflation is set to rise with higher gasoline prices, the central bank sees effectively no "broadening" into non-energy prices. If the conflict doesn't escalate further, the bank should see oil prices gradually moderate, which should help ease hike expectations, added National Bank.

Ultimately, the bank continues to expect the BoC to remain sidelined until 2027 though it's clear the risks are skewed towards earlier tightening.

相關文章

Australia

布倫瑞克公司維持季度股利每股0.44美元,將於6月15日支付給5月18日登記在冊的股東。

Price: $78.25, Change: $+3.79, Percent Change: +5.09%

$BC
Australia

Ero Copper 的評級從“與行業持平”上調至“跑贏大盤”,National Bk 認為其自由現金流前景良好,且“相對不受持續成本壓力的影響”。

Price: $34.47, Change: $+1.12, Percent Change: +3.36%

$ERO.TO
Australia

奧本海默稱,Vertex製藥公司對其新興的腎臟業務充滿信心

奧本海默週二發布的一份報告指出,Vertex Pharmaceuticals (VRTX) 的管理層對其新興的腎臟疾病治療產品線充滿信心,並表示該產品線最終可能與囊性纖維化治療產品線相媲美,甚至超越後者。 報告稱,Alyftrek 的強勁市場接受度令人鼓舞,奧本海默預計,在美國和國際市場,Alyftrek 將繼續增長,這主要得益於初治患者、此前停止囊性纖維化治療的患者以及轉用 Alyftrek 的患者群體的積極採用。 報告還指出,Alyftrek 在年輕患者群體中的普及以及在歐洲市場更廣泛的應用,應有助於其長期成長。此外,該券商表示,Journavx 的管理層仍有信心在 2026 年實現處方總量的三倍成長。 報告稱,管理層對 Pove 的前景充滿信心,並且 Pove 近期已完成提交,這表明 FDA 可能在年底前做出決定。 奧本海默表示,Inaxaplin是下一個關鍵催化劑,其2期AMPLIFIED研究結果預計將於下半年公佈,而先前的預期為2026年中期。 奧本海默維持對Vertex Pharmaceuticals的「跑贏大盤」評級,目標價為600美元。Price: $423.92, Change: $-5.93, Percent Change: -1.38%

$VRTX